Another Supernus epilepsy drug gets FDA nod Reuters India (Reuters) - Supernus Pharmaceuticals Inc's experimental epilepsy drug Oxtellar XR won marketing approval from the U.S. Food and Drug Administration, the second drug approval for the company since it went public in May. Oxtellar XR's final marketing ... Supernus (SUPN) Gets FDA Approval for Oxtellar XRStreetInsider.com (subscription)
0 comments:
Post a Comment